## MRNA: Moderna, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 13.6% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($26.95)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Amundi Sells 425,861 Shares of Moderna, Inc. $MRNA**
- Source: MarketBeat | 20251210T083144 | Neutral | Relevance: 99%
-  Amundi significantly reduced its stake in Moderna, Inc. by selling 425,861 shares, representing a 31.9% decrease in its holdings. Despite this, other hedge funds like Natixis Advisors LLC, Charles Schwab Investment Management Inc., Invesco Ltd., Nuveen LLC, and Public Sector Pension Investment Board increased their positions in the company. Moderna's stock currently has a "Reduce" consensus rating from analysts, with a target price of $29.46.

**2. Dir Hussain Files To Sell 504 Of Moderna Inc [MRNA]**
- Source: TradingView | 20251209T150944 | Neutral | Relevance: 99%
-  Dir Hussain, a Director at Moderna Inc (MRNA), filed a Form 144 with the SEC on December 9, 2025, proposing to sell 504 shares of restricted securities. This sale is scheduled for December 9, 2025, through Fidelity Brokerage Services and is being executed pursuant to a prearranged trading plan (10b5-1).

**3. Moderna on track to extend gains for the seventh straight trading day**
- Source: MSN | 20251211T212334 | Bullish | Relevance: 98%
- Moderna is poised to extend its winning streak for the seventh consecutive trading day. The company's stock performance indicates continued positive momentum in the market.

**4. Moderna to Host Investor Event – Analyst Day**
- Source: Savannah Morning News | 20251209T200908 | Neutral | Relevance: 98%
- Moderna, Inc. announced its Investor Event – Analyst Day will be held on Thursday, November 20, 2025, at 9:00 a.m. ET. Management will present the company's development, commercial strategy, and key business considerations. A live webcast and archived replay will be available on Moderna's investor relations website.

**5. Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products**
- Source: TradingView | 20251210T213658 | Bullish | Relevance: 98%
-  Nanexa AB has signed a license and option agreement with Moderna, Inc. for the development of PharmaShell®-based products. This agreement grants Moderna a license to use Nanexa’s PharmaShell® drug delivery platform for an initial compound and options for up to four additional compounds, with Nanexa receiving a USD 3 million upfront payment and up to USD 500 million in potential milestone payments plus royalties. The collaboration aims to leverage PharmaShell® technology, which uses atomic layer deposition, to enhance the release profile and stability of Moderna’s compounds.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Piper Sandler | $63 | $69 | -9% |
| 2025-11-21 | RBC Capital | $25 | $28 | -11% |
| 2025-11-21 | Leerink Partner | $18 | $15 | +20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Piper Sandler | reit | Overweight |
| 2025-11-21 | RBC Capital | main | Sector Perform |
| 2025-11-21 | Leerink Partner | main | Underperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.00M) |
| Sells | 4 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-1.2%)
- Blackrock Inc.: 7.6% (+3.2%)
- BAILLIE GIFFORD & CO: 5.6% (-1.1%)
- State Street Corpora: 4.4% (-0.9%)
- FMR, LLC: 3.1% (-37.4%)

### Key Risks

1. High short interest (21.2%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.61 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.9x), low leverage (D/E 0.30). Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.6B |
| Beta | 1.11 |
| 52W Range | $22.28 - $48.92 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.61 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from 8.6% to 13.6% (+4.9% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (13.6% > 10.0%), caution on chasing. MRS_5 at 3.9% confirms short-term momentum alignment. AM_20 at 16.0% shows strong absolute momentum above own 20MA. Outperforming sector by 15.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.60), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 13.59% (CS: 97) | Strong |
| RSI_14 | 66.9 | Neutral |
| MACD Histogram | 0.60 | Bullish |
| vs SMA20 | 1.160x | Above |
| vs SMA50 | 1.136x | Above |
| vs SMA200 | 1.076x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $29.63
- **Stop Loss:** $26.95 (9.0% risk)
- **Target:** $32.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 514
- **Position Value:** $15,229.82
- **Portfolio %:** 15.23%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-12 (Est: $-2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-2.18 | $-0.51 | +76.6% |
| 2025Q2 | $-2.97 | $-2.13 | +28.3% |
| 2025Q1 | $-3.18 | $-2.52 | +20.7% |
| 2024Q4 | $-2.76 | $-2.91 | -5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*